Cortical dysplasia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:15:15 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cortical dysplasia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effectiveness of Sirolimus for Treating Drug-Resistant Epilepsy in Children with Rare Brain Disorders Linked to mTOR Pathway Activation https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-sirolimus-for-treating-drug-resistant-epilepsy-in-children-with-rare-brain-disorders-linked-to-mtor-pathway-activation/ Wed, 29 Apr 2026 15:04:00 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-sirolimus-for-treating-drug-resistant-epilepsy-in-children-with-rare-brain-disorders-linked-to-mtor-pathway-activation/ This clinical trial is focused on studying the effects of a medication called Rapamune, which contains the active substance sirolimus. The study is aimed at children who have a type of epilepsy that does not respond well to standard treatments. This form of epilepsy is linked to rare conditions affecting the brain, known as mTORopathies. These conditions include focal cortical dysplasia and LEATs, which are associated with the activation of a specific pathway in the brain called the mTOR pathway.

The purpose of the study is to evaluate the safety and effectiveness of Rapamune in reducing seizures in children with these conditions. Participants in the study will receive the medication in the form of an oral solution. The study will monitor the number of seizures experienced by participants and any side effects that may occur. The goal is to see if the medication can reduce seizures by at least 50% in the participants.

Throughout the study, researchers will also assess the overall impact of the treatment on the quality of life for the children and their families. The study will last for a period of time, during which participants will be closely monitored for any changes in their condition and any potential side effects of the treatment. The findings from this study could provide valuable insights into the treatment of drug-resistant epilepsy in children with these rare brain conditions.

]]> Study on Radiprodil for Seizures and Behavioral Symptoms in Patients with Tuberous Sclerosis Complex or Focal Cortical Dysplasia Type II https://clinicaltrials.eu/trial/study-on-radiprodil-for-seizures-and-behavioral-symptoms-in-patients-with-tuberous-sclerosis-complex-or-focal-cortical-dysplasia-type-ii/ Wed, 29 Apr 2026 14:25:27 +0000 https://clinicaltrials.eu/trial/study-on-radiprodil-for-seizures-and-behavioral-symptoms-in-patients-with-tuberous-sclerosis-complex-or-focal-cortical-dysplasia-type-ii/ This clinical trial is focused on studying the effects of a medication called Radiprodil in patients with two specific conditions: Tuberous Sclerosis Complex and Focal Cortical Dysplasia Type II. These conditions can cause seizures and behavioral symptoms, and the study aims to understand how Radiprodil can help manage these issues. Radiprodil is given as an oral suspension, which means it is a liquid medicine taken by mouth.

The purpose of the study is to assess the safety and tolerability of Radiprodil, as well as how the body processes the medication. Participants will receive multiple doses of Radiprodil that are adjusted individually. The study will also look at how the medication affects seizure frequency and behavioral symptoms over time. Participants will be monitored for any side effects, changes in vital signs, and other health indicators throughout the study.

The study is open-label, meaning both the participants and the researchers know which treatment is being administered. It will involve regular check-ups and assessments to track the effects of Radiprodil on the participants’ conditions. The study will also use tools like electronic diaries to record seizure activity and other symptoms. The goal is to gather comprehensive data on how Radiprodil can benefit patients with these specific neurological conditions.

]]>